Trial Profile
Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Allergic and Eosinophilic Severe Asthma: a Pragmatic Multicenter Trial in Belgium
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary) ; Omalizumab (Primary)
- Indications Allergic asthma; Eosinophilia
- Focus Therapeutic Use
- Acronyms PREDICTUMAB
- 26 Oct 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 26 Oct 2022 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2023.
- 02 Nov 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.